Dasatinib: A new step in molecular target therapy

Annals of Oncology

Volumn 18, Issue SUPPL. 6, 2007, Pages

  Olivieri, Attilio ^a   Manzione, L ^a  

^a SAN CARLO HOSPITAL   (Italy)

Author keywords

Bcr abl kinases; Chronic myeloid leukemia; Dasatinib; Target therapy

Indexed keywords

BCR ABL PROTEIN; DASATINIB; IMATINIB; NILOTINIB; PROTEIN TYROSINE KINASE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ACUTE LYMPHOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER RESISTANCE; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONFERENCE PAPER; CYTOPENIA; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; ENZYME INHIBITION; FLUID RETENTION; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; GRAFT VERSUS HOST REACTION; HUMAN; HYPOCALCEMIA; LEUKEMOGENESIS; LIVER FUNCTION TEST; NEUTROPENIA; PERIPHERAL EDEMA; PLEURA EFFUSION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; SYSTEMIC MASTOCYTOSIS; THROMBOCYTOPENIA; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG RESISTANCE; GENETICS; METABOLISM; REVIEW;

DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, MYELOID, CHRONIC; PROTEIN KINASE INHIBITORS; PYRIMIDINES; THIAZOLES;

EID: 35748952533     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm223     Document Type: Conference Paper

References (30)

1. Deininger MW, Vieira S, Mendiola R et al. BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia, Cancer Res 2000; 60: 2049-2055.
2. Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999; 340: 1330-1340.
3. Druker BJ, Tamura S, Buchdunger E et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561-566.
4. Buchdunger E, Cioffi CL, Law N et al. Abl protein-tyrosine kinase inhibitor ST1571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000; 295: 139-145.
5. Ma Y, Zang S, Metcalfe DO et al. The c-KIT mutation causing human mastocytosis is resistant to ST1571 and other KIT kinase inhibitors: kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 2002; 99: 1741-1744.
6. Druker BJ, Guilhot F, O'Brien SG et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355(23): 2408-2417.
7. Talpaz M, Silver RT, Druker BJ et al. Imatinib induces durable hematologic and cytogenetic responses in patents with accelerated phase chronic myeloid leukemia: Results of a phase 2 study. Blood 2002; 99: 1928-1937.
8. Copland M, Hamilton A, Brick U et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006; 107(11): 4532-4539.
9. Druker BJ, Tapaz M, Resta DJ et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-1103.
10. Mauro MJ. Defining and managing imatinib resistance. Hematology Am Soc Hematol Educ Program 2006: 219-225.
11. Hochhaus A, Kreil S, Corbin AS et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002; 16: 2190-2196.
12. Gorre ME, Mohammed M, Ellwood K et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876-880.
13. Hughes TP, Kaeda J, Branford S et al. Frequency Of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003; 349: 1423-1432.
14. Shah NP, Tran C, Lee FY et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004; 305(5682): 399-401.
15. O'Hare T, Walters DK, Stoffregen EP et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005; 65(11): 4500-4505.
16. Lombardo LJ, Lee FY, Chen P et al. Discovery of
17. Schittenhelm MM, Shiraga S, Schroeder A et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res. 2006; 66(1): 473-481.
18. Talpaz M, Shah NP, Kantarjian H et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. New Engl J Med 2006; 354(24): 2531-2541.
19. Cortes J, Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 2006 doi 10.1 182/ blood-2006-09-046888.
20. Guilhot F, Apperley J, Shah N et al. A phase II study of dasatinib in patients with accelerated phase chronic myeloid leukemia (CML) who are resistant or intolerant to imatinib: First results of the CA180005 'START-A' study. Blood 2005; 106: 16a (Abstr 39).
21. Hochhaus A. Dasatinib induces notable hematologic and cytogenetic responses in chronic phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2006 doi 10.1 182/blood-2006-09-047266.
22. Quintas-Cardama A, Kantarjian H, Jones D et al. Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. Blood 2007; 109(2): 497-499.
23. Kantarjian H, Pasquini R, Hamerschlak N et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukaemia after failure of first-line imatinib: A randomized phase-II trial. Blood 2007; doi 10. 1182/blood-2006-11-056028.
24. Soverini S, Martinelli G, Colarossi S et al. Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia. J Clin Oncol 2006; 24(33): 51-52.
25. Shah NP, Lee FY, Luo R et al. Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood 2006; 108(1): 286-291.
26. Evans TRJ, Morgan JA, Van den Abbeele AD. Phase I close-escalation study of the SRC and multi-kinase inhibitor BMS-354825 in patients (pts) with GIST and other solid tumors. J Clin Oncol 2005; 23: 3034.
27. Laird AD, Li G, Moss KG et al. Src family kinase activity is required for signal tranducer and activator of transcription 3 and focal adhesion kinase phosphorylation and vascular endothelial growth factor signaling in vivo and for anchorage-dependent and -independent growth of human tumor cells. Mol Cancer Ther 2003; 2: 461-469.
28. Chen Z, Lee FY, Bhalla KN et al. Patent inhibition of platelet-derived growth factor-induced responses in vascular smooth muscle cells by BMS-354825 (dasatinib). Mol Pharmacol 2006; 69(5): 1527-1533.
29. Svegliati S, Olivieri A, Campelli N et al. Stimulatory antibodies to PDGF receptor in patients with extensive chronic graft versus host disease. Blood 2007; 0: Blood-2007-01-0710430.
30. Bradeen HA, Eide CA, O'Hare T et al. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: High efficacy of drug combinations. Blood 2006; 108(7): 2332-2338.